In light of data from PRODIGE7, for patients with peritoneal metastasis from colon cancer, do you still offer HIPEC?

I think the PRODIGE 7 trial, while “negative” for the addition of HIPEC to cytoreduction, was an important trial in highlighting a potentially useful treatment approach for metastatic colorectal cancer with peritoneal only disease.

The median survivals are encouraging for patients who receive initia...

In my practice, I leave the decision use HIPEC in addition CRS to my surgical colleagues. Of late, I have seen a roughly 50/50 split in HIPEC/No HIPEC use, largely related to disease burden at the time of surgery.

As for the pre-operative chemotherapy, these patients will all get at least 6 months o...